In published trials, 60–75% of chronic wounds treated with cell or exosome therapy achieved closure or substantial reduction (>90% area healing) within 16 weeks. Outcomes are better for small (≤10 cm²), acute-to-subacute wounds (6 months–1 year old) than for large, longstanding wounds. Patients with uncontrolled diabetes or severe vascular insufficiency show lower healing rates.
Chronic wound cell and exosome therapy has been subject to 59 completed trials, with 7 currently enrolling participants. Trials span diabetic foot ulcers (majority), pressure wounds, and mixed aetiology chronic wounds. Closure rates (percentage of wounds achieving full epithelial coverage) in treated cohorts typically range from 55–85% over 8–16 weeks, compared to reported historical control rates of 20–40% for advanced wounds. Exosome-based studies specifically show wound-area reduction averaging 45–70% at 12 weeks. Trial heterogeneity in wound selection, cell dose, and delivery (topical, intradermal injection, or fibrin-scaffold embedding) limits meta-analysis.
Suis-je un candidat? → · Chronic Wounds & Ulcers: full overview → · Coût Plaies et Ulcères Chroniques → · Cost →
Médicalement examiné par l'équipe éditoriale de StemCellAtlas avec the Stem Plus medical team (physicians & scientists · GMP-certified Sofia laboratory · 25+ yrs international experience) de la clinique partenaire Stem Plus (Sofia), selon les directives ISSCR, FDA et EMA. Educational information, not medical advice; figures indicative.
Médecine régénérative certifiée GMP au cœur de l'UE — à partir de 3 000–8 000 €, une fraction des prix américains ou allemands. Protocoles personnalisés pour patients de plus de 50 pays.
Évaluation médicale gratuite